UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

NICE’s own analysis shows that around one ... and the devaluation of the pound has wiped up to 15% off the value of UK pharma businesses. Pharma leaders are warning that they are running out ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

Andrew McConaghie reports. The recent annual IMS Health UK Market Access Summit brought pharma together with leaders from NICE, the Cancer Drugs Fund, patient organisation Genetic Alliance UK ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

The UK pharma industry can expect resolutions on a ... approvals by the National Institute for Health and Care Excellence (NICE) under its chief executive Dr Samantha Roberts, who he described ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s (LSE: AZN) Truqap ...